Impact of ALTTO Results on Patients With HER2-Positive Breast Cancer

Video

In this video, Dr. Sledge discusses what the negative results of the ALTTO trial mean for women with HER2-positive breast cancer.

George W. Sledge, Jr, MD, division of oncology at the Stanford University Medical Center, discusses the results of the ALTTO trial (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation). Following surgery, the trial randomized patients with HER2-positive breast cancer into four treatment arms: trastuzumab alone, lapatinib alone, trastuzumab followed by lapatinib (sequential therapy), or the combination of the two drugs (concurrent therapy).

In this video, Dr. Sledge shares with our audience how despite the negative result, data from this trial may be used to inform other clinical trials, and discusses what other ongoing trials oncologists will be looking at to address questions about adjuvant therapy for women with HER2-positive breast cancer.

Related Videos
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
Related Content